[go: up one dir, main page]

EP0574466B1 - Expression rekombinanter proteine in attenuierten bakterien - Google Patents

Expression rekombinanter proteine in attenuierten bakterien Download PDF

Info

Publication number
EP0574466B1
EP0574466B1 EP92905914A EP92905914A EP0574466B1 EP 0574466 B1 EP0574466 B1 EP 0574466B1 EP 92905914 A EP92905914 A EP 92905914A EP 92905914 A EP92905914 A EP 92905914A EP 0574466 B1 EP0574466 B1 EP 0574466B1
Authority
EP
European Patent Office
Prior art keywords
bacterium
attenuated
vaccine according
protein
salmonella
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP92905914A
Other languages
English (en)
French (fr)
Other versions
EP0574466A1 (de
Inventor
Ian George Charles
Steven Neville Chatfield
Neil Fraser Fairweather
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919104596A external-priority patent/GB9104596D0/en
Priority claimed from GB919121208A external-priority patent/GB9121208D0/en
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Publication of EP0574466A1 publication Critical patent/EP0574466A1/de
Application granted granted Critical
Publication of EP0574466B1 publication Critical patent/EP0574466B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • This invention relates to vaccines containing attenuated bacteria capable of expressing a heterologous protein.
  • Virulent strains of Salmonella can be attenuated by introducing specific mutations into genes required for survival and growth in vivo .
  • Attenuated variants which establish self limiting, clinically insignificant infections can be considered as potential live oral vaccines against Salmonella infections.
  • Ty21a is an attenuated variant of Salmonella typhi , which harbours mutations in galE and other unknown attenuating lesions, and is licensed for use in many countries as a live oral typhoid vaccine.
  • Salmonella aro mutants which have an auxotrophic requirement for several aromatic compounds, have been shown to be effective oral vaccines in mice, sheep, cattle, chickens and more recently they have been shown to be attenuated and immunogenic in volunteers.
  • Salmonella double aro mutants are disclosed in EP-A-0322237.
  • Salmonella cya crp double mutants are also effective oral vaccines.
  • Salmonellae can be considered as carriers of heterologous antigens to the mucosal immune system. This is because Salmonellae can be delivered via the oral route and are potent immunogens being able to stimulate systemic and local cellular and antibody responses. Heterologous antigens from bacteria, viruses and parasites can be delivered to the host using Salmonella vaccines.
  • a vaccine comprising a pharmaceutically acceptable carrier or diluent and, as active ingredient, an attenuated bacterium which contains a promoter whose activity is induced by anaerobic conditions operably linked to a DNA sequence encoding a heterologous protein comprising an antigenic determinant of a pathogenic organism. Stable expression of the heterologous protein can be obtained in vivo .
  • Any suitable bacterium may be employed, for example a Gram-negative bacterium.
  • Some Gram-negative bacteria such as Salmonella invade and grow within eucaryotic cells and colonise mucosal surfaces.
  • the attenuated bacterium may therefore be selected from the genera Salmonella , Bordetella , Vibrio , Haemophilus , Neisseria and Yersinia .
  • the attenuated bacterium may be an attenuated strain of enterotoxigenic Escherichia coli .
  • S. typhi the cause of human typhoid
  • S. typhimurium the cause of salmonellosis in several animal species
  • S. enteritidis - a cause of food poisoning in humans
  • S. typhi the cause of human typhoid
  • S. typhimurium the cause of salmonellosis in several animal species
  • S. enteritidis - a cause of food poisoning in humans
  • choleraesuis - a cause of salmonellosis in pigs
  • Bordetella pertussis the cause of whooping cough
  • Haemophilus influenzae - a cause of meningitis
  • Neisseria gonorrhoeae the cause of gonorrhoea
  • Yersinia - a cause of food poisoning.
  • Attenuation of the bacterium may be attributable to a non-reverting mutation in a gene in the aromatic amino acid biosynthetic pathway of the bacterium.
  • genes involved in the synthesis of chorismate, the branch point compound in the aromatic amino acid biosynthetic pathway are at least ten genes involved in the synthesis of chorismate, the branch point compound in the aromatic amino acid biosynthetic pathway.
  • aroA (5-enolpyruvylshikimate-3-phosphate synthase)
  • aroC chorismate synthase
  • aroD 3-dihydroquinate dehydratase
  • aroE shikimate dehydrogenase
  • an attenuated bacterium harbours a non-reverting mutation in each of two discrete genes in its aromatic amino acid biosynthetic pathway.
  • Such bacteria are disclosed in EP-A-0322237.
  • Double aro mutants which are suitable are aroA aroC , aroA aroD and aroA aroE mutant bacteria.
  • Other bacteria having mutations in other combinations of the aroA , aroC , aroD and aroE genes are however useful.
  • Salmonella double aro mutants for example double aro mutants of S.typhi or S.typhimurium, in particular aroA aroC , aroA aroD and aroA aroE mutants.
  • the attenuated bacterium may harbour a non-reverting mutation in a gene concerned with the regulation of one or more other genes (EP-A-0400958).
  • the mutation occurs in the ompR gene or another gene involved in regulation.
  • There are a large number of other genes which are concerned with regulation and are known to respond to environmental stimuli Ronson et al , Cell 49 , 579-581).
  • This type of attenuated bacterium may harbour a second mutation in a second gene.
  • the second gene is a gene encoding for an enzyme involved in an essential biosynthetic pathway, in particular genes involved in the pre-chorismate pathway involved in the biosynthesis of aromatic compounds.
  • the second mutation is therefore preferably in the aroA , aroC or aroD gene.
  • Attenuated bacterium is one in which attenuation is brought about by the presence of a non-reverting mutation in DNA of the bacterium which encodes a protein that is produced in response to environmental stress, or in DNA of the bacterium which encodes a protein that regulates the expression of DNA encoding a protein that is produced in response to environmental stress.
  • a non-reverting mutation may be a deletion, insertion, inversion or substitution.
  • a deletion mutation may be generated using a transposon.
  • proteins that are produced in response to environmental stress include heat shock proteins (which are produced in response to a temperature increase above 42°C); nutrient deprivation proteins (which are produced in response to levels of essential nutrients such as phosphates or nitrogen which are below that which the microorganism requires to survive); toxic stress proteins (which are produced in response to toxic compounds such as dyes, acids or possibly plant exudates); or metabolic disruption proteins (which are produced in response to fluctuations in for example ion levels affecting the microorganisms ability to osmoregulate, or vitamin or co-factor levels such as to disrupt metabolism).
  • heat shock proteins which are produced in response to a temperature increase above 42°C
  • nutrient deprivation proteins which are produced in response to levels of essential nutrients such as phosphates or nitrogen which are below that which the microorganism requires to survive
  • toxic stress proteins which are produced in response to toxic compounds such as dyes, acids or possibly plant exudates
  • metabolic disruption proteins which are produced in response to fluctuations in for example ion levels affecting the micro
  • a heat shock protein is the one encoded by the htrA gene, also characterised as degP .
  • Other proteins are encoded by genes known to be involved in the stress response such as grpE , groEL , (moPA), dnaK , groES , lon and dnaJ .
  • proteins There are many other proteins encoded by genes which are known to be induced in response to environmental stress (Ronson et al , Cell 49 , 579-581). Amongst these the following can be mentioned: the ntrB/ntrC system of E.
  • an attenuated bacterium should not revert back to the virulent state.
  • the probability of this happening with a mutation in a single DNA sequence is considered to be small.
  • the risk of reversion occurring with a bacterium attenuated by the presence of mutations in each of two discrete DNA sequences is considered to be insignificant.
  • a preferred attenuated bacterium is therefore one in which attenuation is brought about (1) by the presence of a mutation in a DNA sequence which encodes a protein that is produced in response to environmental stress, or in a DNA sequence which encodes a protein that regulates the expression of DNA encoding a protein that is produced in response to environmental stress and (2) by the presence of a mutation in a second DNA sequence.
  • the second DNA sequence preferably encodes an enzyme involved in an essential auxotrophic pathway or is a sequence whose product controls the regulation of osmotically responsive genes, i.e. ompR , (Infect and Immun 1989 2136-2140).
  • the mutation is in a DNA sequence involved in the aromatic amino acid biosynthetic pathway, more particularly the DNA sequences encoding aroA , aroC or aroD.
  • Attenuated bacteria may be constructed by the introduction of a mutation into the DNA sequence by methods known to those skilled in the art (Maniatis, Molecular Cloning and Laboratory Manual, 1982).
  • Non-reverting mutations can be generated by introducing a hybrid transposon Tn phoA into, for example, S.typhimurium strains.
  • Tn pho A can generate enzymatically active protein fusions of alkaline phosphatase to periplasmic or membrane proteins.
  • the Tn pho A transposon carries a gene encoding kanamycin resistance. Transductants are selected that are kanamycin resistant by growing colonies on an appropriate selection medium.
  • Alternative methods include cloning the DNA sequence into a vector, e.g. a plasmid or cosmid, inserting a selectable marker gene into the cloned DNA sequence, resulting in its inactivation.
  • a plasmid carrying the inactivated DNA sequence and a different selectable marker can be introduced into the organism by known techniques (Maniatis, Molecular Cloning and Laboratory Manual, 1982). It is then possible by suitable selection to identify a mutant wherein the inactivated DNA sequence has recombined into the chromosome of the microorganism and the wild-type DNA sequence has been rendered non-functional in a process known as allelic exchange.
  • the vector used is preferably unstable in the microorganism and will be spontaneously lost.
  • the mutated DNA sequence on the plasmid and the wild-type DNA sequence may be exchanged by a genetic cross-over event. Additional methods eliminate the introduction of foreign DNA into vaccine strains at the site of mutations and the introduction of antibiotic resistant markers into the strains.
  • the heterologous antigen which an attenuated bacterium is capable of expressing comprises an antigenic determinant of a pathogenic organism.
  • the antigen may be derived from a virus, bacterium, fungus, yeast or parasite.
  • the heterologous protein therefore typically comprises an antigenic sequence derived from a virus, bacterium, fungus, yeast or parasite.
  • the antigenic sequence may be derived from a type of human immunodeficiency virus (HIV) such as HIV-1 or HIV-2, hepatitis A or B virus, human rhinovirus such as type 2 or type 14, herpes simplex virus, poliovirus type 2 or 3, foot-and-mouth disease virus, influenza virus, coxsackie virus, the cell surface antigen CD4 and Chlamydia trachomatis .
  • HIV human immunodeficiency virus
  • the antigen may comprise the CD4 receptor binding site from HIV, for example from HIV-1 or -2.
  • Other useful antigens include E. coli heat labile toxin B subunit (LT-B), E. coli K88 antigens, P.69 protein from B. pertussis , tetanus toxin fragment C and antigens of flukes, mycoplasma, roundworms, tapeworms, rabies virus and rotavirus.
  • a preferred promoter for use in controlling the expression of the heterologous protein is the nirB promoter.
  • the nirB promoter has been isolated from E. coli, where it directs expression of an operon which includes the nitrite reductase gene nirB (Jayaraman et al , J. Mol. Biol. 196, 781-788, 1987), and nirD , nirC and cysG (Peakman et al , Eur. J. Biochem. 191 , 315-323, 1990). It is regulated both by nitrite and by changes in the oxygen tension of the environment, becoming active when deprived of oxygen (Cole, Biochim. Biophys. Acta, 162 , 356-368, 1968). Response to anaerobiosis is mediated through the protein FNR, acting as a transcriptional activator, in a mechanism common to many anaerobic respiratory genes.
  • references to the nirB promoter refer to the promoter itself or a part or derivative thereof which is capable of promoting expression of a coding sequence under anaerobic conditions.
  • the sequence which we have in fact used and which contains the nirB promoter is:
  • An attenuated bacterium used according to the present invention may be prepared by transforming an attenuated bacterium with a DNA construct comprising a promoter whose activity is induced by anaerobic conditions, such as the nirB promoter, operably linked to a DNA sequence encoding a heterologous protein. Any suitable transformation technique may be employed, such as electroporation. In this way, an attenuated bacterium capable of expressing a protein heterologous to the bacterium may be obtained. A culture of the attenuated bacterium may be grown under aerobic conditions. A sufficient amount of the bacterium is thus prepared for formulation as a vaccine, with minimal expression of the heterologous protein occurring.
  • the DNA construct is typically a replicable expression vector comprising the nirB promoter operably linked to a DNA sequence encoding the heterologous protein.
  • the nirB promoter may be inserted in an expression vector, which already incorporates a gene encoding the heterologous protein, in place of the existing promoter controlling expression of the protein.
  • the expression vector should of course be compatible with the attenuated bacterium into which the vector is to be inserted.
  • the expression vector is provided with appropriate transcriptional and translational control elements including, besides the nirB promoter, a transcriptional termination site and translational start and stop codons.
  • An appropriate ribosome binding site is provided.
  • the vector typically comprises an origin of replication and, if desired, a selectable marker gene such as an antibiotic resistance gene.
  • the vector may be a plasmid.
  • the vaccine is advantageously presented in a lyophilised form, for example in a capsular form, for oral administration to a patient.
  • a lyophilised form for example in a capsular form, for oral administration to a patient.
  • Such capsules may be provided with an enteric coating comprising, for example, Eudragate "S”, Eudragate “L”, Cellulose acetate, cellulose phthalate or hydroxypropylmethyl cellulose.
  • the lyophilised material may be reconstituted prior to administration, e.g. as a suspension. Reconstitution is advantageously effected in a buffer at a suitable pH to ensure the viability of the organisms.
  • a sodium bicarbonate preparation is advantageously administered before each administration of the vaccine.
  • the vaccine may be prepared for parenteral administration, intranasal administration or intramammary.
  • the attenuated bacterium of the invention may be used in the prophylactic treatment of a host, particularly a human host but also possibly an animal host.
  • An infection caused by a microorganism, especially a pathogen, may therefore be prevented by administering an effective dose of an attenuated bacterium according to the invention.
  • the bacterium then expresses a heterologous protein capable of raising antibody to the microorganism.
  • the dosage employed will be dependent on various factors including the size and weight of the host, the type of vaccine formulated and the nature of the heterologous protein. However, for attenuated S.typhi a dosage comprising the oral administration of from 10 9 to 10 11 S.typhi organisms per dose is generally convenient for a 70kg adult human host.
  • Figures 1 to 4 show the abilities of isolates of S.typhimurium to grow in vivo in the liver, spleen, Peyers patches and mesenteric lymph nodes respectively of BALB/c mice.
  • the x-axis denotes days after infection
  • the y-axis denotes log 10 viable organisms per organ
  • ⁇ denotes isolate BRD509
  • ⁇ denotes isolate BRD847
  • o denotes isolate BRD743
  • ⁇ denotes no ampicillin and ---- denotes ampicillin added.
  • Figure 5 shows anti-tetanus toxin fragment C titres of mouse sera.
  • the x-axis shows the types of bacteria used to challenge the mice. The number of doses is shown in brackets.
  • the y-axis denotes absorbance readings at 492nm.
  • Expression plasmid pTETnir15 was constructed from pTETtac115 (Makoff et al , Nucl. Acids Res. 17 10191-10202, 1989) by replacing the EcoRI-ApaI region (1354bp) containing the lacI gene and tac promoter with the following pair of oligos 1 and 2:
  • oligonucleotides were synthesized on a Pharmacia Gene Assembler and the resulting plasmids confirmed by sequencing (Makoff et al , Bio/Technology 7 , 1043-1046, 1989).
  • an intermediate strain S.typhimurium LB5010 (r - m + ) (Bullas and Ryo, J. Bact. 156 , 471-474, 1983), was transformed with pTETnir15. Colonies expressing fragment C were detected by antibiotic selection followed by colony immunoblotting with anti-tetanus toxin fragment C sera. Colonies were grown overnight on nitrocellulose filters aerobically and then induced by incubating under anaerobic conditions for four hours prior to immunoblotting. One strain that was stably expressing fragment C was used to prepare plasmid DNA.
  • BRD743 (BRD509 harbouring pTET85) and of BRD847 to grow in vivo was compared after oral administration to BALB/c mice.
  • pTET85 was constructed from pTETtac115 (Makoff et al , Nucl. Acids Res. 17 , 10191-10202, 1989) by deleting the 1.2kb Eco RI fragment carrying the lacI gene. This resulted in the constitutive expression of fragment C in Salmonella strains. Numbers of bacteria were enumerated in livers, spleens, Peyers patches and mesenteric lymph nodes. The bacteria isolated from mice were also assessed for their ability to grow on plates containing ampicillin as an indicator of the percentage of organisms still retaining the plasmid expressing fragment C. The results are shown in Figures 1 to 4.
  • mice Groups of twenty mice were incubated orally with 5 x 10 9 cells per mouse of either BRD743, BRD847 or BRD509. On day 25 sera were collected from all mice and analysed by ELISA for anti-tetanus antibodies. All mice vaccinated with BRD847 had detectable anti-fragment C antibody at 25 days whereas those vaccinated with BRD743 or BRD509 did not (Fig. 5). On day 25 ten mice from each group were boosted by oral inoculation with a similar amount of homologous organisms. ELISA analysis of the serum taken from these mice at day 46 showed that the anti-fragment C responses had been boosted for groups inoculated with BRD743 and BRD847. The titres for those mice boosted with BRD847 was significantly higher than for those mice boosted with BRD743. Mice boosted orally with BRD509 failed to produce a detectable antibody response to fragment C.
  • mice vaccinated orally with BRD743, 847 and 509 were tested for immunity against tetanus toxin challenge after one or two doses of the immunising strain.
  • Groups of twenty mice received one single oral dose of 5 x 10 9 organisms and groups of ten mice were challenged on day 25 with 500 50% lethal doses of tetanus toxin (see Table 1).
  • Mice vaccinated with BRD847 were completely protected against challenge after a single oral dose whereas those vaccinated with BRD743 were only partially protected (2/10 survivors).
  • the remaining groups of 10 mice received a second dose of organisms (5 x 10 9 ) on day 25 and were challenged on day 46 (after the 1st dose).
  • mice immunised with BRD847 were completely protected after challenge with tetanus toxin whereas those immunised with BRD743 were only partially protected (5/10).
  • BRD847 is an effective single dose oral vaccine against tetanus toxin challenge in mice.
  • Groups of mice were also challenged with tetanus toxin after receiving 1 and 2 intravenous doses of 10 5 organisms of BRD847 and BRD743. All mice were fully protected against challenge with tetanus toxin after 1 or 2 doses of vaccine strain.
  • mice surviving tetanus challenge SL1344 aroA aroD 8.6x10 9 1 0/10 (BRD509) 7.4x10 9 2 0/10 SL1344 aroA aroD 6.4x10 9 1 2/10 pTET85(BRD743) 8.2x10 9 2 5/10 SL1344 aroA aroD 9.5x10 9 1 10/10 pTETnir15(BRD847) 7.5x10 9 2 9/9

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Claims (22)

  1. Impfstoff, umfassend einen pharmazeutisch akzeptablen Träger oder Verdünnungsstoff und, als Wirkstoff, ein abgeschwächtes Bakterium, das einen Promotor enthält, dessen Aktivität durch anaerobe Bedingungen induziert wird, der funktionsfähig an eine DNA-Sequenz gebunden ist, die ein heterologes Protein kodiert, das eine antigenische Determinante eines pathogenen Organismus umfaßt.
  2. Impfstoff gemäß Anspruch 1, worin das abgeschwächte Bakterium ein abgeschwächter Stamm von Salmonella ist.
  3. Impfstoff gemäß Anspruch 2, worin das abgeschwächte Bakterium ein abgeschwächter Stamm von Salmonella typhi oder Salmonella typhimurium ist.
  4. Impfstoff gemäß einem der vorhergehenden Ansprüche, worin die Abschwächung des Bakteriums einer nicht-umkehrenden Mutation in einem Gen im aromatischen Aminosäure-Biosyntheseweg zuschreibbar ist.
  5. Impfstoff gemäß einem der vorhergehenden Ansprüche, worin die Abschwächung des Bakteriums einer nicht-umkehrenden Mutation in der DNA des Bakteriums zuschreibbar ist, die ein Protein kodiert, das als Reaktion auf Umweltbelastung erzeugt wird, oder in der DNA des Bakteriums, die ein Protein kodiert, das die Expression von DNA reguliert, die ein Protein kodiert, das als Antwort auf Umweltbelastung erzeugt wird.
  6. Impfstoff gemäß Anspruch 4, worin das abgeschwächte Bakterium eine nicht-umkehrende Mutation in jedem von zwei diskreten Genen in seinem aromatischen Aminosäure-Biosyntheseweg beherbergt.
  7. Impfstoff gemäß Anspruch 6, worin das abgeschwächte Bakterium eine aroA aroC-, aroA aroD- oder aroA aroE-Mutante ist.
  8. Impfstoff gemäß einem der vorhergehenden Ansprüche, worin der im Bakterium enthaltene Promotor der nirB-Promotor ist.
  9. Impfstoff gemäß einem der vorhergehenden Ansprüche, worin die im Bakterium enthaltene heterologe Protein-Kodierungssequenz eine antigenische Sequenz kodiert, die aus einem Virus, Bakterium, Pilz, einer Hefe oder einem Parasiten stammt.
  10. Impfstoff gemäß Anspruch 9, worin die heterologe Protein-Kodierungssequenz das P69-Protein aus Bordetella pertussis oder Tetanustoxin-Fragment C kodiert.
  11. Abgeschwächtes Bakterium, wie in einem der vorhergehenden Ansprüche definiert, zur Verwendung in einem Verfahren zur prophylaktischen Behandlung eines menschlichen oder tierischen Wirts gegen Infektion durch einen Mikroorganismus.
  12. Abgeschwächtes Salmonella-Bakterium, wie in einem der Ansprüche 2 bis 10 definiert.
EP92905914A 1991-03-05 1992-03-05 Expression rekombinanter proteine in attenuierten bakterien Expired - Lifetime EP0574466B1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB919104596A GB9104596D0 (en) 1991-03-05 1991-03-05 Production of recombinant proteins
GB9104596 1991-03-05
GB9121208 1991-10-04
GB919121208A GB9121208D0 (en) 1991-10-04 1991-10-04 Vaccines
PCT/GB1992/000387 WO1992015689A1 (en) 1991-03-05 1992-03-05 Expression of recombinant proteins in attenuated bacteria

Publications (2)

Publication Number Publication Date
EP0574466A1 EP0574466A1 (de) 1993-12-22
EP0574466B1 true EP0574466B1 (de) 1999-05-19

Family

ID=26298523

Family Applications (1)

Application Number Title Priority Date Filing Date
EP92905914A Expired - Lifetime EP0574466B1 (de) 1991-03-05 1992-03-05 Expression rekombinanter proteine in attenuierten bakterien

Country Status (18)

Country Link
US (2) US5547664A (de)
EP (1) EP0574466B1 (de)
JP (1) JP3415145B2 (de)
KR (1) KR100240182B1 (de)
AT (1) ATE180280T1 (de)
AU (1) AU664360B2 (de)
CA (1) CA2099841C (de)
CZ (1) CZ285118B6 (de)
DE (1) DE69229221T2 (de)
DK (1) DK0574466T3 (de)
ES (1) ES2131069T3 (de)
FI (1) FI110008B (de)
GR (1) GR3030778T3 (de)
HU (1) HU219535B (de)
NO (1) NO309331B1 (de)
PL (1) PL170938B1 (de)
SK (1) SK55593A3 (de)
WO (1) WO1992015689A1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003060105A1 (en) * 2001-12-28 2003-07-24 University Of Southern Queensland Defective entities and uses therefor

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9209118D0 (en) * 1992-04-28 1992-06-10 Sb 120 Amsterdam Bv Vaccine compositions
KR950702635A (ko) 1992-07-31 1995-07-29 크리스틴 헬렌 수덴 감쇠 박테리아에서 재조합 융합 단백질의 발현(Expression of recombinant fusion proteins in attenuated bacteria)
GB9401787D0 (en) 1994-01-31 1994-03-23 Medeva Holdings Bv Vaccine compositions
EP0712442B1 (de) * 1993-07-30 2002-03-27 Medeva Holdings B.V. Rekombinante tetc-fusionsprotein enthaltene impfstoffzusammensetzungen
GB2295394B (en) * 1994-01-31 1997-09-24 Medeva Holdings Bv DNA encoding a fusion protein comprising the C fragment of tetanus toxin
GB9401795D0 (en) * 1994-01-31 1994-03-23 Medeva Holdings Bv Vaccines
AUPM612494A0 (en) * 1994-06-08 1994-06-30 Csl Limited Treatment or prevention of helicobacter infection
US6254874B1 (en) * 1995-04-13 2001-07-03 President And Fellows Of Harvard College Attenuated auxotrophic microorganisms having a combination of non-attenuating mutations and method for making same
US6190657B1 (en) 1995-06-07 2001-02-20 Yale University Vectors for the diagnosis and treatment of solid tumors including melanoma
GB9521568D0 (en) * 1995-10-20 1995-12-20 Lynxvale Ltd Delivery of biologically active polypeptides
US20030125278A1 (en) * 1997-08-13 2003-07-03 Tang De-Chu C. Immunization of animals by topical applications of a salmonella-based vector
US6080849A (en) 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
CN1253551C (zh) 1997-09-10 2006-04-26 维昂药品公司 减毒的遗传修饰肿瘤靶向细菌
US6905691B1 (en) 1997-12-11 2005-06-14 Celltech Pharma Europe Limited Vaccines containing attenuated bacteria
GB9806449D0 (en) 1998-03-25 1998-05-27 Peptide Therapeutics Ltd Attenuated bacteria useful in vaccines
US6585975B1 (en) * 1998-04-30 2003-07-01 Acambis, Inc. Use of Salmonella vectors for vaccination against helicobacter infection
FR2778922A1 (fr) * 1998-05-19 1999-11-26 Pasteur Institut Polynucleotides contenant des sequences de regulation de la synthese de toxines de clostridium, et microorganismes les comprenant
US6413768B1 (en) * 1998-12-02 2002-07-02 University Of Maryland Expression plasmids
US6790950B2 (en) 1999-04-09 2004-09-14 Pharmacia & Upjohn Company Anti-bacterial vaccine compositions
EP1860117A3 (de) 1999-04-09 2008-09-03 Pharmacia & Upjohn Company LLC Antibakterielle Impfstoffzusammensetzungen
US20040009936A1 (en) 1999-05-03 2004-01-15 Tang De-Chu C. Vaccine and drug delivery by topical application of vectors and vector extracts
US6962696B1 (en) 1999-10-04 2005-11-08 Vion Pharmaceuticals Inc. Compositions and methods for tumor-targeted delivery of effector molecules
GB0024203D0 (en) * 2000-10-03 2000-11-15 Peptide Therapeutics Ltd Stabilisation of plasmid inheritance in bacteria
EP1343870A4 (de) * 2000-11-09 2005-07-13 Univ Queensland Bakterielle expressionssysteme
US7780961B2 (en) * 2001-05-03 2010-08-24 Actogenix N.V. Self-containing Lactococcus strain
GB0121998D0 (en) 2001-09-11 2001-10-31 Acambis Res Ltd Attenuated bacteria useful in vaccines
GB0205376D0 (en) * 2002-03-07 2002-04-24 Royal Holloway University Of L Spore germination
AU2003250250B2 (en) * 2002-06-19 2008-02-14 Intrexon Actobiotics Nv Methods and means to promote gut absorption
AU2003298291A1 (en) * 2002-11-15 2004-06-15 Universiteit Gent Self-containing lactobacillus strain
US8029777B2 (en) 2004-08-13 2011-10-04 Marshall Barry J Helicobacter system and uses thereof
CN102078622A (zh) 2004-08-13 2011-06-01 巴里.J.马沙尔 细菌递送系统
US8748126B2 (en) 2005-11-29 2014-06-10 Actogenix N.V. Induction of mucosal tolerance to antigens
EP2517723B1 (de) 2006-09-18 2019-11-06 The Board of Trustees of The University of Arkansas Zusammensetzungen und Verfahren zur Verstärkung von Immunreaktionen
CA2675297C (en) 2007-01-25 2019-05-07 Actogenix Nv Treatment of immune disease by mucosal delivery of antigens
WO2009059018A1 (en) * 2007-10-30 2009-05-07 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to flagellated bacterium
PT3097926T (pt) 2007-11-01 2020-01-08 Univ Guelph Composições e métodos de potenciação das respostas imunitárias frente a eimeria
DK2525817T3 (en) 2010-01-21 2017-10-02 Univ Arkansas Vaccine vectors and methods for enhancing immune responses
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
AU2011264772B2 (en) 2010-06-09 2015-07-16 The Board Of Trustees Of The University Of Arkansas Vaccine and methods to reduce Campylobacter infection
CN102477440A (zh) * 2010-11-29 2012-05-30 南京大学 治疗基因在厌氧组织靶向递送和选择性稳定表达方法及应用
US10183069B2 (en) 2011-03-21 2019-01-22 Altimmune Inc. Rapid and prolonged immunologic-therapeutic
MX348172B (es) 2011-03-21 2017-06-02 Altimmune Inc Sustancia inmunologica terapeutica rapida y prolongada.
DK2956165T3 (da) 2013-02-14 2019-12-02 Univ Arkansas Sammensætninger og fremgangsmåder til forstærkning af immunreaktioner på Eimeria eller begrænsning af Eimeria-infektion
US10376571B2 (en) 2013-03-15 2019-08-13 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to enteric pathogens
WO2017192671A1 (en) 2016-05-03 2017-11-09 The Board Of Trustees Of The University Of Arkansas Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837151A (en) * 1980-05-19 1989-06-06 The Board Of Trustees Of The Leland Stanford Junior University, Stanford University Live vaccines comprising two mutations and foreign antigen
DE3735381A1 (de) * 1987-03-31 1989-05-03 Boehringer Mannheim Gmbh Rekombinante dna zur reprimierbaren und induzierbaren expression von fremdgenen
GB8730037D0 (en) * 1987-12-23 1988-02-03 Wellcome Found Vaccines
JPH0284172A (ja) * 1988-07-21 1990-03-26 Smithkline Beckman Corp 異種遺伝子の発現能を有し、組換え型ワクチンとして有用なサルモネラ形質転換体
DE3926076A1 (de) * 1989-04-21 1990-10-25 Boehringer Mannheim Gmbh Rekombinante dna und expressionsvektor
GB8912330D0 (en) * 1989-05-30 1989-07-12 Wellcome Found Live vaccines
GB9007194D0 (en) * 1990-03-30 1990-05-30 Wellcome Found Live vaccines
GB9104596D0 (en) * 1991-03-05 1991-04-17 Wellcome Found Production of recombinant proteins

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003060105A1 (en) * 2001-12-28 2003-07-24 University Of Southern Queensland Defective entities and uses therefor

Also Published As

Publication number Publication date
FI933757L (fi) 1993-08-26
GR3030778T3 (en) 1999-11-30
WO1992015689A1 (en) 1992-09-17
HU9302492D0 (en) 1993-11-29
FI933757A0 (fi) 1993-08-26
HU219535B (hu) 2001-05-28
FI110008B (fi) 2002-11-15
CA2099841C (en) 2003-02-25
CA2099841A1 (en) 1992-09-06
PL170938B1 (pl) 1997-02-28
HUT66833A (en) 1995-01-30
ES2131069T3 (es) 1999-07-16
JPH06505158A (ja) 1994-06-16
EP0574466A1 (de) 1993-12-22
US5683700A (en) 1997-11-04
CZ285118B6 (cs) 1999-05-12
NO932423L (no) 1993-07-02
NO309331B1 (no) 2001-01-15
PL296702A1 (en) 1993-07-26
DE69229221T2 (de) 1999-09-23
DK0574466T3 (da) 1999-11-08
US5547664A (en) 1996-08-20
AU664360B2 (en) 1995-11-16
ATE180280T1 (de) 1999-06-15
AU1350892A (en) 1992-10-06
CZ100593A3 (en) 1994-01-19
SK55593A3 (en) 1993-10-06
JP3415145B2 (ja) 2003-06-09
DE69229221D1 (de) 1999-06-24
NO932423D0 (no) 1993-07-02
KR100240182B1 (ko) 2000-01-15

Similar Documents

Publication Publication Date Title
EP0574466B1 (de) Expression rekombinanter proteine in attenuierten bakterien
US5424065A (en) Vaccines containing avirulent phop-type microorganisms
US5804194A (en) Vaccines containing a salmonella bacteria attenuated by mutation of the htra gene
AU584963B2 (en) Non-reverting double mutant salmonella live vaccines
AU640344B2 (en) Novel non-reverting shigella flexneri linve vaccines
US5851519A (en) Live vaccines
US8318148B2 (en) Attenuated bacteria useful in vaccines
EP0322237B1 (de) Vakzine
RU2126447C1 (ru) Способ получения аттенуированного штамма бактерий salmonella и вакцина
PL171476B1 (en) Method of obtaining attenuated salmonella bacterium
AU659995C (en) Live vaccines

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19930424

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL

17Q First examination report despatched

Effective date: 19961105

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: THE WELLCOME FOUNDATION LIMITED

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

RBV Designated contracting states (corrected)

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

REF Corresponds to:

Ref document number: 180280

Country of ref document: AT

Date of ref document: 19990615

Kind code of ref document: T

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: BRAUN & PARTNER PATENT-, MARKEN-, RECHTSANWAELTE

Ref country code: CH

Ref legal event code: EP

REF Corresponds to:

Ref document number: 69229221

Country of ref document: DE

Date of ref document: 19990624

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2131069

Country of ref document: ES

Kind code of ref document: T3

ET Fr: translation filed
ITF It: translation for a ep patent filed
REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20090321

Year of fee payment: 17

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090305

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MC

Payment date: 20110228

Year of fee payment: 20

Ref country code: DK

Payment date: 20110310

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20110317

Year of fee payment: 20

Ref country code: FR

Payment date: 20110317

Year of fee payment: 20

Ref country code: LU

Payment date: 20110415

Year of fee payment: 20

Ref country code: SE

Payment date: 20110311

Year of fee payment: 20

Ref country code: CH

Payment date: 20110314

Year of fee payment: 20

Ref country code: AT

Payment date: 20110228

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20110217

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20110302

Year of fee payment: 20

Ref country code: BE

Payment date: 20110311

Year of fee payment: 20

Ref country code: GB

Payment date: 20110302

Year of fee payment: 20

Ref country code: ES

Payment date: 20110414

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 69229221

Country of ref document: DE

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 69229221

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: V4

Effective date: 20120305

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: DK

Ref legal event code: EUP

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20120304

BE20 Be: patent expired

Owner name: THE *WELLCOME FOUNDATION LTD

Effective date: 20120305

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20120306

REG Reference to a national code

Ref country code: GR

Ref legal event code: MA

Ref document number: 990401865

Country of ref document: GR

Effective date: 20120306

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20120304

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK07

Ref document number: 180280

Country of ref document: AT

Kind code of ref document: T

Effective date: 20120305

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20130723

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20120306